Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen’s Repatha To Launch Next Week; Narrow Indication Mirrors Rival Praluent

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approves PCSK9 inhibitor for use with statin therapy in adults with familial hypercholesterolemia or atherosclerotic cardiovascular disease; drug priced at $14,100 annually for every two weeks administration.

Advertisement

Related Content

Praluent Coverage: Being First May Not Matter As Payers Await Repatha

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register